FHN Stock Analysis: First Horizon | NYSE
Banks - Regional | NYSE, USA | Market Cap: 11.079m USD | 12M Return: 7.2% | US3205171057 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 126M
EPS Trend: 96.9%
Qual. Beats: 0
Rev. Trend: -64.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
First Horizon Corporation (NYSE: FHN) is a U.S.-based bank holding company headquartered in Memphis, Tennessee, that conducts operations through its subsidiary First Horizon Bank. As a large-cap regional bank within the Financials sector, it focuses on serving customers across defined geographic markets rather than operating a national branch network. The company was founded in 1864 and adopted its current name in April 2004 after operating as First Horizon National Corporation.
The company operates through three reportable segments: Regional Banking, Specialty Banking, and Corporate. Its service offerings span commercial and business banking, consumer banking, private client and wealth management, financial planning, trust and asset management, and treasury management solutions. Lending activities include asset-based lending, commercial real estate, equipment finance and leasing, energy finance, healthcare finance, transportation and logistics finance, mortgage warehouse lending, and franchise finance.
First Horizon also provides capital markets and institutional services, including fixed income sales, trading, underwriting, and derivative strategies, as well as loan syndications, portfolio advisory, and mortgage origination. Additional revenue streams include transaction processing services, credit card products, and the sale of mutual funds, reflecting the diversified income mix typical of mid-to-large regional banks seeking to reduce reliance on net interest income alone.
- Net interest margin compresses as Fed rate cuts pressure Regional Banking yields
- Specialty Banking loan growth driven by healthcare and franchise finance expansion
- Capital deployment accelerates share buybacks after terminated TD Bank acquisition
| Net Income: 712.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.12 > 1.0 |
| NWC/Revenue: -45.23% < 20% (prev -1.26k%; Δ 1.21k% < -1%) |
| CFO/TA 0.03 > 3% & CFO 2.22b > Net Income 712.0m |
| Net Debt (3.19b) to EBITDA (1.02b): 3.12 < 3 |
| Current Ratio: 0.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (474.0m) vs 12m ago -7.06% < -2% |
| Gross Margin: 60.68% > 18% (prev 64.48%; Δ -3.79% > 0.5%) |
| Asset Turnover: 4.95% > 50% (prev 5.76%; Δ -0.81% > 0%) |
| Interest Coverage Ratio: 0.66 > 6 (EBIT TTM 944.0m / Interest Expense TTM 1.44b) |
| A: -0.02 (Total Current Assets 930.0m - Total Current Liabilities 2.80b) / Total Assets 84.3b |
| B: 0.06 (Retained Earnings 5.21b / Total Assets 84.3b) |
| C: 0.01 (EBIT TTM 944.0m / Avg Total Assets 83.8b) |
| D: 0.12 (Book Value of Equity 8.83b / Total Liabilities 75.2b) |
| Altman-Z'' = 0.25 = B |
As of November 20, 2026, the stock is trading at USD 22.22 with a total of 8,025,727 shares traded. Over the past week, the price has changed by -5.08%, over one month by -2.24%, over three months by -10.04% and over the past year by +7.15%.
Current recommended Stop Loss: 21.50 (which is 3.2% or 1.5 ATR below the current price).
First Horizon has received a consensus analysts rating of 3.62. Therefore, it is recommended to hold FHN.
- StrongBuy: 5
- Buy: 3
- Hold: 13
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.1 | 22.1% |
P/E Trailing = 16.9281
P/E Forward = 10.3199
P/S = 3.6469
P/B = 1.3598
P/EG = 1.7557
Revenue TTM = 4.14b USD
EBIT TTM = 944.0m USD
EBITDA TTM = 1.02b USD
Long Term Debt = 1.32b USD (from longTermDebt, last quarter)
Short Term Debt = 2.80b USD (from shortTermDebt, last quarter)
Debt = 4.12b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.19b USD (calculated: Debt 4.12b - CCE 930.0m)
Enterprise Value = 14.3b USD (11.1b + Debt 4.12b - CCE 930.0m)
Interest Coverage Ratio = 0.66 (Ebit TTM 944.0m / Interest Expense TTM 1.44b)
EV/FCF = 6.60x (Enterprise Value 14.3b / FCF TTM 2.16b)
FCF Yield = 15.14% (FCF TTM 2.16b / Enterprise Value 14.3b)
FCF Margin = 52.16% (FCF TTM 2.16b / Revenue TTM 4.14b)
Net Margin = 17.19% (Net Income TTM 712.0m / Revenue TTM 4.14b)
Gross Margin = 60.68% ((Revenue TTM 4.14b - Cost of Revenue TTM 1.63b) / Revenue TTM)
Gross Margin QoQ = 55.53% (prev 70.24%)
Tobins Q-Ratio = 0.17 (Enterprise Value 14.3b / Total Assets 84.3b)
Interest Expense / Debt = 34.85% (Interest Expense 1.44b / Debt 4.12b)
Taxrate = 21.74% (202.0m / 929.0m)
NOPAT = 738.7m (EBIT 944.0m * (1 - 21.74%))
Current Ratio = 0.33 (Total Current Assets 930.0m / Total Current Liabilities 2.80b)
Debt / Equity = 0.47 (Debt 4.12b / totalStockholderEquity, last quarter 8.83b)
Debt / EBITDA = 3.12 (Net Debt 3.19b / EBITDA 1.02b)
Debt / FCF = 1.48 (Net Debt 3.19b / FCF TTM 2.16b)
Total Stockholder Equity = 9.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.85% (Net Income 712.0m / Total Assets 84.3b)
RoE = 7.91% (Net Income TTM 712.0m / Total Stockholder Equity 9.00b)
RoCE = 9.14% (EBIT 944.0m / Capital Employed (Equity 9.00b + L.T.Debt 1.32b))
RoIC = 0.88% (NOPAT 738.7m / Invested Capital 84.1b)
WACC = 13.67% (E(11.1b)/V(15.2b) * Re(8.61%) + D(4.12b)/V(15.2b) * Rd(34.85%) * (1-Tc(0.22)))
Discount Rate = 8.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.67 | Cagr: -6.17%
[DCF] Terminal Value 62.73% ; FCFF base≈1.44b ; Y1≈1.66b ; Y5≈2.44b
[DCF] Fair Price = 33.11 (EV 18.8b - Net Debt 3.19b = Equity 15.6b / Shares 470.9m; r=13.67% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.90 | EPS CAGR: 20.52% | SUE: 0.0 | # QB: 0
Revenue Correlation: -64.75 | Revenue CAGR: -3.70% | SUE: -0.18 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.54 | Chg30d=-0.96% | Revisions=+0% | Analysts=15
EPS current Year (2026-12-31): EPS=2.14 | Chg30d=-0.05% | Revisions=+19% | GrowthEPS=+13.4% | GrowthRev=+2.7%
EPS next Year (2027-12-31): EPS=2.33 | Chg30d=+0.30% | Revisions=+15% | GrowthEPS=+8.6% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +15% (up=22, down=16)